Target Name: GON4L
NCBI ID: G54856
Review Report on GON4L Target / Biomarker Content of Review Report on GON4L Target / Biomarker
GON4L
Other Name(s): Gon-4 like, transcript variant 5 | GON-4-like protein (isoform c) | gon-4 like | GON-4-like protein | YARP | Gon-4 homolog | GON4L variant 3 | gon-4 homolog | RP11-243J18.4 | GON4L_HUMAN | GON-4 homolog | GON-4-like protein (isoform b) | KIAA1606 | YY1AP-related protein1 | YY1AP related protein | Gon-4 like, transcript variant 4 | GON4L variant 5 | Gon-4 like, transcript variant 3 | GON4L variant 4 | GON-4 | GON4 | GON-4-like protein (isoform a) | 2610100B20Rik | GON4L variant 2 | Gon-4 like, transcript variant 2 | RP11-101O6.1

GON4L: A Potential Drug Target and Biomarker for Gout

Gout is a chronic autoimmune condition that causes joint inflammation and pain, often affecting the big toe joint. It is characterized by attacks of severe pain, redness, and swelling in the affected joint, which can last for days or weeks. While there are several treatments available for gout, finding new treatments that work well and are free from side effects can be difficult. A new potential drug target and biomarker for gout, GON4L, has been identified, which could pave the way for new treatments for this painful condition.

GON4L: The Potential Drug Target

GON4L is a gene that has not been previously identified as associated with gout. However, studies have shown that gout is associated with increased levels of uric acid in the body. Uric acid is a byproduct of the body's metabolism and can be found in many foods, including organ meats, anchovies, sardines, beer, and red wine. When the body has too much uric acid in its system, it can form crystals in the joints, which can cause joint pain and inflammation.

GON4L has been shown to be involved in the regulation of uric acid levels in the body. Studies have shown that when GON4L is expressed in the body, it can help regulate the levels of uric acid and prevent the formation of crystals in the joints. This suggests that GON4L may be a useful target for new treatments for gout.

GON4L: The Potential Biomarker

In addition to its potential as a drug target, GON4L has also been shown to be a potential biomarker for gout. Biomarkers are molecules that are produced by the body that can be used as indicators of a particular disease or condition. In the case of gout, biomarkers may be used to diagnose the disease and to monitor the effectiveness of different treatments.

One of the challenges in treating gout is identifying accurate biomarkers that can be used to monitor the disease and the effectiveness of different treatments. GON4L has the potential to be such a biomarker, as it has been shown to be involved in the regulation of uric acid levels in the body. This suggests that GON4L may be able to serve as a marker for the severity of gout symptoms and the effectiveness of different treatments.

Future Research

While the potential for GON4L as a drug target and biomarker for gout is promising, further research is needed to fully understand its role. Researchers will need to conduct more studies to determine the exact mechanisms by which GON4L regulates uric acid levels in the body and how it can be used as a biomarker for gout.

In addition, researchers will need to study the safety and effectiveness of GON4L as a potential drug target and biomarker for gout. This will involve administering GON4L to patients with gout and evaluating the results of any potential treatments.

Conclusion

GON4L is a gene that has not been previously identified as associated with gout. However, studies have shown that gout is associated with increased levels of uric acid in the body. GON4L has been shown to be involved in the regulation of uric acid levels in the body, which suggests that it may be a useful target for new treatments for gout. Additionally, GON4L has the potential to be a biomarker for gout, which could be used to diagnose the disease and monitor the effectiveness of different treatments. Further research is needed to fully understand the potential of GON4L as a drug target and biomarker for gout.

Protein Name: Gon-4 Like

Functions: Has transcriptional repressor activity, probably as part of a complex with YY1, SIN3A and HDAC1. Required for B cell lymphopoiesis

The "GON4L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GON4L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GON7 | GOPC | GORAB | GORASP1 | GORASP2 | GOSR1 | GOSR2 | GOT1 | GOT1-DT | GOT1L1 | GOT2 | GOT2P1 | GP1BA | GP1BB | GP2 | GP5 | GP6 | GP9 | GPA33 | GPAA1 | GPALPP1 | GPAM | GPANK1 | GPAT2 | GPAT3 | GPAT4 | GPATCH1 | GPATCH11 | GPATCH2 | GPATCH2L | GPATCH3 | GPATCH4 | GPATCH8 | GPBAR1 | GPBP1 | GPBP1L1 | GPC1 | GPC1-AS1 | GPC2 | GPC3 | GPC4 | GPC5 | GPC5-AS1 | GPC5-AS2 | GPC6 | GPC6-AS1 | GPC6-AS2 | GPCPD1 | GPD1 | GPD1L | GPD2 | GPER1 | GPHA2 | GPHB5 | GPHN | GPI | GPI transamidase complex | GPI-GlcNAc transferase complex | GPIHBP1 | GPKOW | GPLD1 | GPM6A | GPM6B | GPN1 | GPN2 | GPN3 | GPNMB | GPR101 | GPR107 | GPR108 | GPR119 | GPR12 | GPR132 | GPR135 | GPR137 | GPR137B | GPR137C | GPR139 | GPR141 | GPR142 | GPR143 | GPR146 | GPR148 | GPR149 | GPR15 | GPR150 | GPR151 | GPR152 | GPR153 | GPR155 | GPR156 | GPR157 | GPR158 | GPR158-AS1 | GPR15LG | GPR160 | GPR161 | GPR162 | GPR17 | GPR171